Domestic erythropoietin market contested by 3 pharmaceutical firms

Business sources says that the domestic erythropoietin (EPO) market has emerged as an arena of tripartite competition CJ Corporation's Epokine, Choong-wae Pharm's Recormon (Roche licensing-in) and Daiichi-Kirin's Aranesp, as the market size is expected to grow to 33.0 billion next year with an average growth rate of 10 percent.

Launched in 1998, the independently developed Epokine accounted...